Amgen to acquire Horizon Therapeutics for $27.8 billion

Amgen announced a cash offer to acquire Horizon Therapeutics plc for $116.50 per share, valuing the company at approximately $27.8 billion on a fully diluted basis, with an enterprise value of about $28.3 billion.

“The Acquisition values the entire issued and to be issued ordinary share capital of the Company at approximately $27.8 billion on a fully diluted basis.”amgen.com

• 1 source
• amgen.comRule 2.7 Announcement: Amgen Inc to Acquire Horizon ...Dec 12, 2022

Summarized from public sources; check the original articles before acting on it.